Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
Allogene Therapeutics (NASDAQ: ALLO), a clinical-stage biotech company focused on developing allogeneic CAR T (AlloCAR T™) therapies for cancer and autoimmune diseases, has announced its participation in four major investor conferences:
• TD Cowen's 6th Annual Oncology Innovation Summit (May 27, 9:30AM PT)
• Jefferies Global Healthcare Conference (June 4, 1:55PM PT)
• Goldman Sachs 46th Annual Global Healthcare Conference (June 10, 5:00AM PT)
• Oppenheimer Innovators in I&I Summit (June 25, 9:45AM PT)
Webcasts of the presentations will be available on the company's website (www.allogene.com) under the Investors tab, with replays accessible for approximately 30 days after the events.
Allogene Therapeutics (NASDAQ: ALLO), un'azienda biotecnologica in fase clinica specializzata nello sviluppo di terapie CAR T allogeniche (AlloCAR T™) per il cancro e le malattie autoimmuni, ha annunciato la sua partecipazione a quattro importanti conferenze per investitori:
• 6° Summit Annuale sull'Innovazione in Oncologia di TD Cowen (27 maggio, 9:30 PT)
• Conferenza Globale sulla Sanità di Jefferies (4 giugno, 13:55 PT)
• 46ª Conferenza Globale sulla Sanità di Goldman Sachs (10 giugno, 5:00 PT)
• Summit Innovatori in I&I di Oppenheimer (25 giugno, 9:45 PT)
Le presentazioni saranno trasmesse in webcast sul sito web dell'azienda (www.allogene.com) nella sezione Investitori, con le registrazioni disponibili per circa 30 giorni dopo gli eventi.
Allogene Therapeutics (NASDAQ: ALLO), una empresa biotecnológica en etapa clínica enfocada en desarrollar terapias CAR T alogénicas (AlloCAR T™) para el cáncer y enfermedades autoinmunes, ha anunciado su participación en cuatro importantes conferencias para inversores:
• 6º Cumbre Anual de Innovación en Oncología de TD Cowen (27 de mayo, 9:30 AM PT)
• Conferencia Global de Salud de Jefferies (4 de junio, 1:55 PM PT)
• 46ª Conferencia Global de Salud de Goldman Sachs (10 de junio, 5:00 AM PT)
• Cumbre de Innovadores en I&I de Oppenheimer (25 de junio, 9:45 AM PT)
Las presentaciones estarán disponibles en webcast en el sitio web de la compañía (www.allogene.com) bajo la pestaña de Inversores, con repeticiones accesibles aproximadamente 30 días después de los eventos.
Allogene Therapeutics (NASDAQ: ALLO)는 암 및 자가면역 질환을 위한 동종 CAR T(AlloCAR T™) 치료법 개발에 주력하는 임상 단계의 바이오텍 기업으로, 네 차례의 주요 투자자 컨퍼런스에 참여할 예정임을 발표했습니다:
• TD Cowen 제6회 연례 종양학 혁신 서밋 (5월 27일, 오전 9:30 PT)
• Jefferies 글로벌 헬스케어 컨퍼런스 (6월 4일, 오후 1:55 PT)
• Goldman Sachs 제46회 연례 글로벌 헬스케어 컨퍼런스 (6월 10일, 오전 5:00 PT)
• Oppenheimer I&I 혁신가 서밋 (6월 25일, 오전 9:45 PT)
발표 웹캐스트는 회사 웹사이트(www.allogene.com) 투자자 탭에서 제공되며, 행사 후 약 30일간 다시보기 가능합니다.
Allogene Therapeutics (NASDAQ : ALLO), une société biotechnologique en phase clinique spécialisée dans le développement de thérapies CAR T allogéniques (AlloCAR T™) pour le cancer et les maladies auto-immunes, a annoncé sa participation à quatre grandes conférences pour investisseurs :
• 6e Sommet annuel de l'innovation en oncologie de TD Cowen (27 mai, 9h30 PT)
• Conférence mondiale sur la santé de Jefferies (4 juin, 13h55 PT)
• 46e conférence mondiale annuelle sur la santé de Goldman Sachs (10 juin, 5h00 PT)
• Sommet des innovateurs en I&I d'Oppenheimer (25 juin, 9h45 PT)
Les webinaires des présentations seront disponibles sur le site web de la société (www.allogene.com) sous l’onglet Investisseurs, avec des rediffusions accessibles environ 30 jours après les événements.
Allogene Therapeutics (NASDAQ: ALLO), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung allogener CAR-T-Therapien (AlloCAR T™) für Krebs und Autoimmunerkrankungen spezialisiert hat, hat seine Teilnahme an vier bedeutenden Investorenkonferenzen angekündigt:
• TD Cowens 6. jährlicher Oncology Innovation Summit (27. Mai, 9:30 Uhr PT)
• Jefferies Global Healthcare Conference (4. Juni, 13:55 Uhr PT)
• Goldmans Sachs 46. jährliche globale Gesundheitskonferenz (10. Juni, 5:00 Uhr PT)
• Oppenheimer Innovators in I&I Summit (25. Juni, 9:45 Uhr PT)
Webcasts der Präsentationen werden auf der Unternehmenswebsite (www.allogene.com) unter dem Reiter Investoren verfügbar sein, mit Wiedergaben, die etwa 30 Tage nach den Veranstaltungen abrufbar sind.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in four upcoming investor conferences in May and June.
TD Cowen’s 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA
Tuesday, May 27
9:30AM PT/12:30PM ET
Jefferies Global Healthcare Conference
Wednesday, June 4
1:55PM PT/4:55PM ET
Goldman Sachs 46th Annual Global Healthcare Conference
Tuesday, June 10
5:00AM PT/8:00AM ET
Oppenheimer Innovators in I&I Summit
Wednesday, June 25
9:45AM PT/12:45PM ET
Any available webcasts will be posted to the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on the Company's website for approximately 30 days.
About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer and autoimmune disease. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow Allogene Therapeutics on X and LinkedIn.
Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things Allogene’s ability to develop and deliver readily available allogeneic CAR T products for the treatment of cancer and autoimmune disease on-demand, more reliably, and at greater scale to more patients. Various factors may cause material differences between Allogene’s expectations and actual results, including risks and uncertainties related to our product candidates being based on novel technologies, which makes it difficult to predict the time and cost of product candidate development, the safety or efficacy of a product candidate, and whether a product candidate will receive regulatory approval, which could prevent or delay commercialization. These and other risks are discussed in greater detail in Allogene’s filings with the SEC, including without limitation under the “Risk Factors” heading in its Quarterly Report on Form 10-Q for the year ended March 31, 2025. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.
Allogene Media/Investor Contact:
Christine Cassiano
EVP, Chief Corporate Affairs & Brand Strategy Officer
Christine.Cassiano@allogene.com
FAQ
When is Allogene Therapeutics (ALLO) presenting at the Goldman Sachs Healthcare Conference 2025?
What type of therapy is Allogene Therapeutics (ALLO) developing?
How long will the webcasts be available on Allogene's website?
Which investor conferences will Allogene Therapeutics (ALLO) attend in May and June 2025?
